Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
safimaltib (JNJ-6633) / J&J
NCT03900598: A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	Active, not recruiting	1	226	Europe, Japan, US, RoW	JNJ-67856633	Janssen Research & Development, LLC	Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin	12/24	01/26
NCT04876092: A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL	Active, not recruiting	1	45	Europe	JNJ-67856633, Ibrutinib, JNJ-54179060	Janssen Research & Development, LLC	Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin	11/24	12/26
NCT04657224: A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia	Active, not recruiting	1	75	Europe, US, RoW	JNJ-64264681, JNJ-67856633	Janssen Research & Development, LLC	Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia	07/25	12/26